(a)
(b)
(c)
(d)

Figure 2: (a) Heatmap of TMPRSS2-ERG negative tumour samples of the RP cohort (n=256); samples are ordered according to their PDE4D5 score from low to high. (b) Heatmap of TMPRSS2-ERG negative tumour samples of the RP cohort (n=256); samples are ordered according to their PDE4D9 score from low to high. (c) Heatmap of TMPRSS2-ERG positive tumour samples of the RP cohort (n=280); samples are ordered according to their PDE4D7 score from low to high. The legends of the graphs and color coding are defined as ‘Sample ID’: IDs of the 256 TMPRSS2-ERG negative tumour samples of the RP cohort. ‘TMPRSS2-ERG status’: presence (dark green) or absence (light green) of the gene fusion event in a given sample. ‘BCR class’: every patient is coded for the presence (dark yellow) or absence (light yellow) of a BCR (biochemical recurrence) event during the >120 months median follow-up. ‘Metastasis class’: every patient is coded for the presence (dark orange) or absence (light orange) of a metastases event during the >120 months median follow-up). ‘PCa death class’: every patient is coded for the presence (dark red) or absence (light red) of a prostate cancer specific death event during the >120 months median follow-up. PDE4D5, PDE4D7, and PDE4D9 score categories were defined as PDE4D5/7/9 (1-2): PDE4D5/7/9 scores (1 to <2; dark blue); PDE4D5/7/9 (2-3): PDE4D5/7/9 scores (2 to <3; light blue); PDE4D5/7/9 (3-4): PDE4D5/7/9 scores (3 to <4; light pink); PDE4D5/7/9 (4-5): PDE4D5/7/9 scores (4 to <=5; dark pink). (d) RP cohort patient samples (n=31) with the lowest PDE4D5, PDE4D7, and PDE4D9 scores. The legends of the graph and color coding are defined as above with the change of a color coding for BCR, Metastasis, and PCa Death class according to a time interval to the event; light yellow: no event during >120 months median follow-up; light blue: <2 years to the event during >120 months median follow-up; light grey: 2-5 years to the event during >120 months median follow-up; light green: >5 years to the event during >120 months median follow-up.